Home > Riviste > Panminerva Medica > Fascicoli precedenti > Articles online first > Panminerva Medica 2021 Apr 28

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Panminerva Medica 2021 Apr 28

DOI: 10.23736/S0031-0808.20.03910-5

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Atorvastatin rescues pulmonary artery hypertension via inhibiting the AKT/ERK-dependent PDGF-BB/HIF-1α axis

Jianfei CHEN 1, Mingbao SONG 2, Dehui QIAN 3, Linqiong LIU 1, Kun YANG 1, Yunfeng SHOU 1, Hanru ZHAO 1, Li ZHANG 4

1 Department of Cardiology, Banan People’s Hospital of Chongqing, Chongqing, China; 2 Department of Cardiology, Kangxin Hospital of Chongqing, Chongqing, China; 3 Department of Cardiology, Xingqiao Hospital, Chongqing, China; 4 Department of Pathology, Southwest Hospital, Chongqing, China


PDF


BACKGROUND: To explore the role of Atorvastatin in rescuing pulmonary artery hypertension (PAH) via inhibiting the AKT/ERK-dependent PDGF-BB/HIF-1α axis.
METHODS: PAH model in rats was established by MCT induction, followed by Atorvastatin intervention. Pulmonary hemodynamic measurement and pulmonary morphological evaluation in rats were conducted. Human pulmonary artery smooth muscle cells (hPASMCs) were subjected to hypoxic exposure or PDGF-BB treatment, followed by Atorvastatin induction. Relative levels of HIF-1α, p-ERK and p-Akt were detected. Viability and apoptosis were respectively determined by cell counting kit-8 (CCK-8) assay and flow cytometry.
RESULTS: Atorvastatin protected PAH-induced increases in RVSP and Fulton’s index in rats. Meanwhile, it inhibited vascular remodeling following PAH by downregulating HIF-1α and PDGF-BB. Hypoxia or PDGF-BB treatment in hPASMCs resulted in upregulation of p-ERK and p-Akt, and viability increase, which were partially abolished by Atorvastatin intervention. In addition, Atorvastatin triggered apoptosis in hypoxia or PDGF-BB-induced hPASMCs.
CONCLUSIONS: Atorvastatin inhibits the activation of HIF-1α and proliferative ability, and triggers apoptosis in hPASMCs exposed to hypoxia or PDGF-BB treatment through inactivating the AKT/ERK pathway.


KEY WORDS: Atorvastatin; AKT/ERK; PDGF-BB; HIF-1α; PAH

inizio pagina